AKT1 and melanoma: This study underlines the aberrant activation of the phosphoinositide 3-kinase-protein kinase B - mammalian target of rapamycin (PI3K-Akt-mTOR) and inactivation of the Hippo-YAP pathway, acting as a tumor suppressor [33] in benign-to-malignant transition in melanomas [32].